CEPHALOSPORINS

1502727 Cephalosporins CARLO ERBA SpA 21 April 1976 [21 April 1975 7 April 1976] 16176/76 Heading C2C The invention comprises novel compounds (I) (including salts thereof) where x is zero, 1 or 2; n is zero or 1; Z is: (1) a cyano group, a carbamoyl group, or a -COOR or -COR group, wherein R is hydrogen or C 1 -C 6 alkyl, (2) a R 1 -SO 2 - group, wherein R 1 is C 1 -C 6 alkyl, amino or salified or unsalified hydroxy, (3) a phenyl group or a pentatomic or hexatomic heteromonocyclic ring containing at least one double bond and at least one heteroatom selected from N, S and O, the phenyl and the heteromonocyclic ring being unsubstituted or substituted by one or more substituents selected from hydroxy, cyano, carboxy, oxo, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, -SH, C 1 -C 6 aliphatic acyl, -CH 2 CN and wherein each of the R groups, being the same or different, is as defined above; A is a direct linkage or has each of the meanings herebelowgiven for A 1 ; A 1 is a C 1 -C 8 branched or straight chain saturated aliphatic hydrocarbon radical, which may be unsubstituted or substituted by one or more substituents selected from OR111, wherein R111 is hydrogen or formyl; halogen; cyano; amino; -COOR or -COR, wherein R is as defined above; and R 1 -SO 2 -, wherein R 1 is as defined above; B is a heterobicyclic ring, other than triazolopyridyl and purinyl, containing at least two double bonds, wherein each of the condensed heteromonocyclic rings, being the same or different, is a pentatomic or hexatomic heteromonocyclic ring containing at least one heteroatom selected from N, S and O, the heterobicyclic ring being unsubstituted or substituted by one or more substituents selected from: (a) hydroxy, cyano, -SH, C 1 -C 6 alkoxy, halogen, C 1 -C 6 aliphatic acyl, -CH 2 CN, -COOR, or wherein R is as defined above; (b) an amino group unsubstituted or substituted by a C 1 -C 6 aliphatic acyl group; (c) a C 1 -C 6 alkyl group, unsubstituted or substituted by one or more substituents selected from hydroxy and halogen; (d) wherein x 1 is zero, 1 or 2 and each of R1 and R11, being the same or different, is hydrogen or C 1 -C 6 alkyl, or R1 and R11, taken together with the nitrogen atom, form a morpholino, piperidino or pyridyl ring; (e) -S-R 1 or -SO-R 1 , wherein R 1 is as defined above, -S-CH 2 CN, -(S) x2 -CH 2 -COOR, wherein x 2 is zero or 1 and R is as defined above; M is hydrogen or a non-toxic pharmaceutically acceptable cation; provided that, when at the same time B is